Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5267-5277

  Hunter, Sally M ^a   Gorringe, Kylie L ^a,b   Christie, Michael ^c,d   Rowley, Simone M ^a   Bowtell, David D ^a,b   Campbell, Ian G ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; PROTEIN P53; RAS PROTEIN;

ARTICLE; BRAF GENE; CANCER INVASION; CARCINOGENESIS; CDKN2A GENE; CDKN2B GENE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; CYSTADENOMA; FEMALE; GENE; GENE ACTIVATION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; OVARY ADENOCARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOMA, MUCINOUS; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84866905581     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1103     Document Type: Article

References (68)

1. DePriest PD, Banks ER, Powell DE, van Nagell JR Jr, Gallion HH, Puls LE, et al. Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women. Gynecol Oncol 1992;47:71-5.
2. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol 1993;169: 181 -2.
3. Chew S, Tham KF, Ratnam SS. A series of ovarian clear cell and endometrioid carcinoma and their association with endometriosis. Singapore Med J 1997;38:289-91. (Pubitemid 127518380)
4. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998;58:1707-12. (Pubitemid 28215097)
5. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: anew model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9. (Pubitemid 46095865)
6. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31: 161 -9.
7. Carlson J, Roh MH, Chang MC, Crum CP. Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol (Oxf) 2008;14:352- 65.
8. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008;14:4067-78.
9. Roelofsen T, van Kempen LC, van der Laak JA, van Ham MA, Bulten J, Massuger LF. Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion? Int J Gynecol Cancer 2012;22:457-64.
10. Laury AR, Ning G, Quick CM, Bijron J, Parast MM, Betensky RA, et al. Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol 2011;35:1759-65.
11. Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih Ie M. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011;35:1605-14.
12. Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, et al. Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol 2011;24:1488-99.
13. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer 2012;131: 938-48.
14. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010;171:45-53.
15. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007;16:1160-6. (Pubitemid 46984953)
16. Seidman JD, Khedmati F. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med 2008;132:1753-60.
17. Wong AK, Seidman JD, Barbuto DA, McPhaul LW, Silva EG. Mucinous metaplasia of the fallopian tube: a diagnostic pitfall mimicking metastasis. Int J Gynecol Pathol 2011;30:36 -40.
18. Barakat RR, Markman M, Randall ME. editors Principles and practice of gynecologic oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
19. Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 2010;116: 1462- 8.
20. Bamias A, Sotiropoulou M, Zagouri F, Trachana P, Sakellariou K, Kostouros E, et al. Prognostic evaluation of tumor type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor. Eur J Cancer 2012; 48:1476-83.
21. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 2009;113:331-4.
22. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004;22:1040-4. (Pubitemid 41095036)
23. Shyr YM, Su CH, Tsay SH, Lui WY Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Ann Surg 1996;223:141-6. (Pubitemid 26065206)
24. Akwari OE, Tucker A, Seigler HF, Itani KM. Hepatobiliary cystadenoma with mesenchymal stroma. Ann Surg 1990;211:18- 27.
25. Devaney K, Goodman ZD, Ishak KG Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol 1994;18:1078-91. (Pubitemid 24337615)
26. Tenti P, Romagnoli S, Pellegata NS, Zappatore R, Giunta P, Ranzani GN, et al. Primary retroperitoneal mucinous cystoadenocarcinomas: an immunohistochemical and molecular study. Virchows Arch 1994;424:53- 7.
27. Hunter SM, Anglesio MS, Sharma R, Gilks CB, Melnyk N, Chiew YE, et al. Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? Clin Cancer Res 2011;17:7273-82.
28. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumors. J Pathol 2004;202:336-40. (Pubitemid 38325243)
29. Thomas NA, Neville PJ, Baxter SW, Campbell IG. Genetic analysis of benign ovarian tumors. Int J Cancer 2003;105:499-505. (Pubitemid 36578554)
30. Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006;103:883-7. (Pubitemid 44821309)
31. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997;79:1581-6. (Pubitemid 27154791)
32. Suzuki M, Saito S, Saga Y, Ohwada M, Sato I. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Cancer Genet Cytogenet 2000;118: 132-5. (Pubitemid 30169214)
33. Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92. (Pubitemid 23113216)
34. Puls LE, Powell DE, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.
35. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000;24:1447-64.
36. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999;23: 617-35. (Pubitemid 29262825)
37. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD, Campbell IG. Localization of an ovarian cancer tumor suppressor gene to a 0.5- cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res 1996;56:719-21. (Pubitemid 26055458)
38. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122:170-6.
39. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003;27:281-92. (Pubitemid 36245793)
40. Gorringe KL, Campbell IG. Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 2009;3:157- 64.
41. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, et al. Identi fication of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 2010;5:e9983.
42. GorringeKL,RamakrishnaM,WilliamsLH, Sridhar A,Boyle SE,Bearfoot JL, et al. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer 2009;48:931-42.
43. Persons DL, Hartmann LC, Herath JF, Keeney GL, Jenkins RB. Fluorescence in situ hybridization analysis of trisomy 12 in ovarian tumors. Am J Clin Pathol 1994;102:775-9.
44. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643- 8.
45. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000. (Pubitemid 35424092)
46. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54. (Pubitemid 34716871)
47. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004;23:379-85. (Pubitemid 38174991)
48. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J, et al. p15Ink4b is a critical tumor suppressor in the absence of p16Ink4a. Nature 2007;448:943 -6.
49. Zhang Z, Rosen DG, Yao JL, Huang J, Liu J. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol 2006;19:1339-43. (Pubitemid 44423081)
50. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumor biology: senescence in premalignant tumors. Nature 2005;436:642. (Pubitemid 41117258)
51. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 2000;119: 929-42.
52. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17: 3112-26. (Pubitemid 38040774)
53. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J, et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signalregulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 2004;64:3428-35. (Pubitemid 38657914)
54. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67. (Pubitemid 38410730)
55. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 2008;128:2003-12. (Pubitemid 352001214)
56. Rabien A, Sanchez-Ruderisch H, Schulz P, Otto N, Wimmel A, Wiedenmann B, et al. Tumor suppressor p16(INK4a) controls oncogenic K-Ras function in human pancreatic cancer cells. Cancer Sci 2012; 103:169-75.
57. Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA. p16(INK4a) and p53 deficiency cooperate in tumorigenesis. Cancer Res 2002;62:2761-5. (Pubitemid 34525758)
58. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004;93:301-6. (Pubitemid 38507593)
59. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009;9:433.
60. Lin WL, Kuo WH, Chen FL, Lee MY, Ruan A, Tyan YS, et al. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann Surg Oncol 2011;18:2388-94.
61. Lin CK, Lin WL, Chen FL, Lee MY, Kuo JF, Ruan A, et al. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization. Int J Gynecol Pathol 2011;30: 372-9.
62. Zhu X, Lu Y, Lu H, Yang W, Tu X, Cai X, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. Hum Pathol 2011;42:1499-504.
63. Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008;6: 1678 - 90.
64. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.Am J Surg Pathol 2003;27:985-93. (Pubitemid 36763545)
65. Young RH, Hart WR. Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. A report of seven cases. Am J Surg Pathol 1989;13:748-56. (Pubitemid 19201945)
66. Young RH. From krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the krukenberg tumor. Adv Anat Pathol 2006;13:205-27. (Pubitemid 44439976)
67. Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001;20:244- 51.
68. Barzon L, Masi G, Boschin IM, Lavezzo E, Pacenti M, Casal Ide E, et al. Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur J Endocrinol 2008;159:77-80. (Pubitemid 351969134)